Table 1 Summary of molecular profiling analyses from various CLIA certified methods in a patient with malignant phyllodes sarcoma
Marker | Result | Details |
|---|---|---|
Focused exome sequencing | ||
NRAS | Mutated | Q61L |
TP53 | Deletion | Also proved by aCGH1 |
RB1 | Mutated | Q504* and K740* |
Array comparative hybridization | ||
Amplifications | Chr. 1, 8 and 9 | CKS1B, MYC and CDKN2A genes |
Deletions | Chr. 10, 11, 17 and 22 | GATA3, CCND1, TP53 and PDGFB gene |
Immunohistochemistry | ||
p-AKT | Positive | Intensity of 2 in 40% of cells |
PDGFRβ | Positive | Intensity of 2 in 90% of cells |
PDGFRα | Positive | Intensity of 2 in 80% of cells |
EGFR | Positive | Intensity of 2 in 70% of cells |
TLE3 | Positive | Intensity of 2 in 35% of cells |
PTEN | Present | Intensity of 2 in 90% of cells |
Kit (CD117) | Negative | No staining |
Morphoproteomic immunohistochemistry | ||
mTOR | Positive | 2+ morpho test |
SPARC | Positive | 2-3+ morpho test |
ER-α | Negative | Morpho test |